
Unlocking Precision in Medicine
.png)
Circular Genomics is a pioneer in precision
medicine, leveraging cutting-edge technology
and proprietary data to uncover insights for
personalized medicine.
​
We're dedicated to advancing circular RNA
biomarkers for accurate diagnosis and treatment
of psychiatric and neurological disorders, aiming
to empower individuals to gain deeper insights
into their mental health and discover optimal
treatment pathways.
​
Through the use of precision medicine, our team of globally recognized experts are striving to create a better understanding of mental health and neurology. We are committed to improving patient outcomes using our innovative technologies and data-driven approach.​
​
“Circular Genomics was founded to guide patients toward a brighter future, illuminating their mental health journey.”
Alexander Hafez
Co-Founder
Director of Operations & Corp. Development

Our Story
February 2021​
Circular Genomics founded by Nikolaos Mellios, Alexander Hafez and Kosmas Karadimitriou​


August 2021​
Circular Genomics opens its first research and development lab in Albuquerque, NM​


January 2022​
Initiated ANTARES study, in collaboration with Centre National de la Recherche Scientifique


February 2023​
Paul Sargeant brought on as industry experienced President and CEO ​



June 2021​
Scientific advisory board is established, consisting of world renowned psychiatric and neurological experts ​
December 2021​
Results of first depression clinical study suggest circular RNA can serve as reliable biomarkers for predicting antidepressant response​ ​
July 2022
Results of EMBARC depression clinical study show implications of circular RNA research for antidepressant response
June 2023
Circular Genomics partners with Dr. Carlos Cruchaga for research of circular RNAs in Alzheimer’s disease ​
Team


Board of Directors
